Adults 45 and older should start routine colorectal cancer screenings. People at higher risk due to family history or other ...

Pfizer’s Talzenna in combi with Xtandi improves survival outcomes in metastatic castration resistant prostate cancer: New York Saturday, February 15, 2025, 11:00 Hrs [IST] Pfize ...

Progression-free survival (PFS) in oligometastatic prostate cancer improved significantly with metastasis-directed therapy ...

Adding talazoparib (Talzenna) to enzalutamide (Xtandi) as initial treatment for metastatic castration-resistant prostate ...

New Data at ASCO GU Show Power of Veracyte’s Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and ...

From 1,085 citations identified, 48 studies with 15,368 men with mCRPC met inclusion criteria. Most studies were retrospective cohorts (n = 39) from Europe (n = 22) and North America (n = 18), with ...

SAN FRANCISCO -- Patients with high-risk prostate cancer had a significantly lower incidence of distant metastasis when ...

The American Cancer Society's chief scientific officer outlines the group's research agenda, including a new project in ...

Positve overall survival data could lead to a label expansion for Pfizer's combination to treat metastatic ...

Alerts delivered via the electronic health record temporarily reduces unnecessary screening and treatment but does not create ...

The 63-year-old musician revealed his stage 4 prostate cancer diagnosis in November 2022, saying his cancer was “asymptomatic ...

Having raised more than $1 million toward cancer research over the past nine years, the tournament is on the road to raising ...